{"type":"trials","record":{"id":28323,"source_id":"clinicaltrials-gov","external_id":"NCT05839041","title":"A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)","brief_summary":"Investigate the Safety, Pharmacokinetics, and Treatment effects of Single and Multi-dose of Intravitreal AVD-104 in participants with geographic atrophy secondary to age-related macular degeneration.","overall_status":"Completed","phases":["PHASE2"],"study_type":"INTERVENTIONAL","sponsor":"Aviceda Therapeutics, Inc.","enrollment":300,"countries":["United States"],"start_date":"2023-05-02","completion_date":"2026-02-18","last_update_date":"2026-09-16","source_url":"https://clinicaltrials.gov/study/NCT05839041","editorial_summary":"A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T00:17:13.08831+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":"SIGLEC","age_range":"55 Years to 90 Years","comparator":"Part 2: High dose AVD-104; Part 2: Low dose AVD-104; Part 2: Avacincaptad","organization":"Aviceda Therapeutics, Inc.","interventions":["AVD-104","Avacincaptad"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Occurrence of Dose Limiting Toxicity in Part 1 — 3 months","The Rate of Change in Area of Geographic Atrophy at Month 12 in Participants in Part 2 — 12 months","Prevention of Vision Loss from Baseline in Participants in Part 2 — 12 months"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE","source_has_results":false},"controlled_terms":["Geographic Atrophy of the Macula","Macular Degeneration","AVD-104","Avacincaptad"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":100,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct05839041","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2023-05-02 to 2026-02-18","comparator":"Part 2: High dose AVD-104; Part 2: Low dose AVD-104; Part 2: Avacincaptad","confidence":"structured-source","population":"ALL · 55 Years to 90 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.796Z","intervention":["AVD-104","Avacincaptad"],"participants":300,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE2","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Occurrence of Dose Limiting Toxicity in Part 1 — 3 months","The Rate of Change in Area of Geographic Atrophy at Month 12 in Participants in Part 2 — 12 months","Prevention of Vision Loss from Baseline in Participants in Part 2 — 12 months"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Abstract contains controlled term: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","abstract","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/28323","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}